The antiplatelet function of prasugrel and clopidogrel

JRCT ID: jRCT1031220254

Registered date:08/08/2022

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Stable coronary artery disease
• Date of first enrollment: 08/08/2022
• Target sample size: 100
• Study type: Observational

Outcome(s)

• Primary Outcome: Platelet agglutination ability(NSR-2)
• Secondary Outcome: Platelet agglutination ability(maximum aggregation rate)

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) Age is 20 years or older at the time of consent acquisition
2) Those who are judged by the doctor in charge to be DAPT indicated due to PCI schedule for stable coronary artery disease
3) Maintenance of aspirin (100 mg / day) as part of standard treatment
4) Those who have received sufficient explanation before participating in this research, and who have obtained sufficient understanding and voluntary written consent of the research subject

Exclude criteria

1) Platelet count<50000000000/L
2) Dialysis patients
3) Baseline ALT> 2.5 times the normal upper limit.
4) Pregnant or lactating women
5) Contraindications for prasugrel, clopidogrel, or stent placement
6) In addition, those who are judged by the principal investigator to be inappropriate as research subjects

Related Information

• Primary Sponsor: Isoda Kikuo